Ranbaxy to introduce dental drug Inersan in India, Nepal

Ranbaxy Laboratories today announced an exclusive in-licensing agreement with C D Pharma to market the Inersan brand in India and Nepal. The patented product, a probiotic preparation, is used for the treatment of dental problems such as periodontitis, gingivitis and halitosis.

''Presently there is no particular drug available for the treatment of this dental problem,'' the company said in a communique. ''Inersan, a natural biological product, shall be a first-of-its-kind to be introduced in India,'' the communique added.

Early-stage Periodontitis (Gum Disease) is painful and causes swollen and bleeding gums. This can lead to serious infection and eventually may cause tooth loss if left untreated. Some dentists recommend surgical options such as flap surgery, soft tissue grafting or bone grafting and guided tissue regeneration.

"In the post patent era, we are driven by the need to in-license differentiated products and the introduction of Inersan tablets consolidates Ranbaxy's position in Dental segment,'' said Sanjeev I Dani, senior vice president and regional director, Asia & CIS, Ranbaxy,

He also added that periodontitis, gingivitis and halitosis are common dental problems which, if ignored, could lead to more serious complications. ''Dental practitioners in India currently do not have any specialised prescription product for these conditions and Inersan tablets address this need for the segment."

Studies carried out over the years have shown that gum disease can affect a person's overall health, the company says. Women with advanced gum diseases are likely to give birth to an underweight or pre-term baby while the ability of oral microbes to cross the placental barrier can expose the fetus to infection.

Cardiac ailment patients have to be more careful to avoid periodontitis because the bacteria from the mouth can cause clotting problems in the cardiovascular system and increase the risk of fatal heart attacks.